Correlation Between Veracyte and Mereo BioPharma

Can any of the company-specific risk be diversified away by investing in both Veracyte and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Mereo BioPharma Group, you can compare the effects of market volatilities on Veracyte and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Mereo BioPharma.

Diversification Opportunities for Veracyte and Mereo BioPharma

-0.76

Correlation Coefficient

Veracyte  Mereo BioPharma

Pay attention - limited upside

The 3 months correlation between Veracyte and Mereo is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of Veracyte i.e., Veracyte and Mereo BioPharma go up and down completely randomly.

Pair Corralation between Veracyte and Mereo BioPharma

Given the investment horizon of 90 days Veracyte is expected to generate 0.74 times more return on investment than Mereo BioPharma. However, Veracyte is 1.35 times less risky than Mereo BioPharma. It trades about 0.1 of its potential returns per unit of risk. Mereo BioPharma Group is currently generating about -0.1 per unit of risk. If you would invest  3,894  in Veracyte on September 22, 2024 and sell it today you would earn a total of  195.00  from holding Veracyte or generate 5.01% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Mereo BioPharma Group

Veracyte

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Mereo BioPharma Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Veracyte and Mereo BioPharma

The main advantage of trading using opposite Veracyte and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.

The idea behind Veracyte and Mereo BioPharma Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.